Until very recently, docetaxel was the only approved agent in castration-resistant prostate
cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years …

There is a growing number of new therapies targeting different pathways that will
revolutionize patient management strategies in castration-resistant prostate cancer (CRPC) …

Importance of the field: Since the introduction of taxane-based chemotherapy for advanced
solid tumors in the 1990s, the median overall survival of patients with metastatic breast …

The results of cytotoxic therapy in the second-line setting of metastatic castration-resistant
prostate cancer have demonstrated that disease is poorly controlled after taxane resistance …

Importance of the field: Castrate-resistant prostate cancer continues to be inadequately
addressed by currently available therapies. Areas covered in this review: This review will …

Prostate cancer is the most common non–skin cancer diagnosed in North America and
affects 1 in 6 men. It is the second to third most common cause of cancer death in men in the …

7. END OF LIFE 95 8. CONCLUSIONS 96 8.1 Implications for research 97 Appendix 1
Cabazitaxel trials identified by the ERG in ClinicalTrials. gov 98 Appendix 2 Quality …

Androgen blockade is the standard treatment of metastatic PCa. However, after a limited
period of time, tumoral cells invariably become resistant to hormone therapy. Docetaxel …

Résumé En dépit d'avancées significatives dans la compréhension des mécanismes
biologiques du cancer de la prostate et de son évolution métastatique, la prise en charge de …

Trotz technischer Fortschritte in der Behandlung des Prostatakarzinoms schreitet die
Erkrankung in 27–54% der Patienten innerhalb von 10 Jahren fort und bedarf einer …